Short, toxic RNAs kill brain cells and may allow Alzheimer’s to develop.
Category: biotech/medical – Page 447
Cedars-Sinai Cancer investigators have used a unique precision medicine and artificial intelligence (AI) tool called the Molecular Twin Precision Oncology Platform to identify biomarkers that outperform the standard test for predicting pancreatic cancer survival. Their study, published in Nature Cancer, demonstrates the viability of a tool that could one day guide and improve treatment for all cancer patients.
“Molecular Twin, which we developed at Cedars-Sinai, can be used to study any tumor type, including pancreatic cancer, which is notoriously difficult to treat,” said Dan Theodorescu, MD, Ph.D., director of Cedars-Sinai Cancer and the PHASE ONE Foundation Distinguished Chair, and senior author of the study. “Using our Molecular Twin technology, we anticipate creating tests that can be used even in locations that lack access to advanced resources and technology, pairing patients with the most effective therapies and expanding the availability of precision medicine.”
Investigators used the Molecular Twin platform to analyze blood and tissue samples from 74 patients with the most common and most aggressive pancreatic cancer type, pancreatic ductal adenocarcinoma. The disease begins in the cells lining ducts that carry digestive enzymes from the pancreas to the small intestine.
Summa Technologiae
Posted in biotech/medical, futurism
„Summa Technologie is a „mother-essay from which most of Lem’s later essayistic books stem. It was written in times when most of the discussed issues – today sometimes quite obvious ones – belonged to the world of fantasy. The ambition behind this project still amazes, especially if we take into consideration that Lem tried to set up a secular edifice of knowledge, competing in its universalism with Saint Thomas Aquinas and his Summa Theologica.
At the same time the book rivals world futurology — in the domain of foreseeing future ways of science and technology. Current generation, interested in biotechnology and informatics, shall find in Lem’s “Summa” the project and prophecy of todays’ successes of these disciplines.
The English translation (University Of Minnesota Press, 2013) is the work of Joanna Zylinska, professor of new media and communications at Goldsmiths, University of London.
LONDON (AP) — U.K. health officials on Monday urged millions of parents to book their children for missed measles, mumps and rubella shots during a sharp increase in the number of measles cases and the lowest vaccination rates in a decade.
The National Health Service is launching a publicity campaign after figures showed there were about 250 confirmed measles cases in parts of England last year. Most cases were in children under 10 years old.
The combined measles, mumps and rubella, or MMR, vaccine is offered in the U.K. in two doses to all children, first at 12 months and then again at 3 years. Vaccination rates have dropped to about 85% nationally, and far lower in parts of London, according to U.K. Health Security Agency chief executive Jenny Harries.
A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.
This story is part of a series on the current progression in Regenerative Medicine. This piece discusses advances in Alzheimer’s therapy.
In 1999, I defined regenerative medicine as the collection of interventions that restore normal function to tissues and organs damaged by disease, injured by trauma, or worn by time. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.
An emerging combination of focused ultrasound therapy with a recently approved medication could be our best treatment for Alzheimer’s disease to date. In the New England Journal of Medicine, Dr. Ali Rezai and colleagues from West Virginia University describe an approach to reduce cerebral amyloid-beta load, a biomarker for neurodegeneration, in patients with Alzheimer’s. While in its preliminary stages, the combination treatment can potentially help thousands, if not millions, suffering from the disease in the near future.
Low mental health associated with worse outcomes after total hip arthroplasty suggests a new study published in the Archives of Orthopaedic and Trauma Surgery.
Poor mental health is difficult to recognize and as a result, its association with recovery from total joint arthroplasty is difficult to assess. The purpose of this study was to investigate the relationship between overall mental health scores and outcomes in the early postoperative period following unilateral total hip arthroplasty (THA). This is a retrospective review of prospectively collected data involving 142 patients who underwent primary unilateral THA. Independent variables included patient demographics and preoperative Patient-Reported Outcomes Measurement Information System (PROMIS), Global Physical Health (GPH) and Global Mental Health (GMH) and Hip Disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS JR) scores as well as diagnoses of depression or anxiety.
The newly discovered cancer-killing abilities of a type of immune cell linked to allergies suggests it could be a new immunotherapy.
Respiratory syncytial virus (RSV), a common infection in children and senior adults, can also infect nerve cells and trigger inflammation leading to nerve damage, according to a new Tulane University study.
RSV can cause mild symptoms such as coughing, sneezing and fever or lead to more severe conditions such as pneumonia or bronchiolitis.
But since the disease was first discovered in 1956, it has been thought to only infect the respiratory tract.
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 million people worldwide, and many patients end up needing dialysis or a kidney transplant by the time they reach their 60s.
Researchers at MIT and Yale University School of Medicine have now found that a compound originally developed as a potential cancer treatment holds promise for treating ADPKD. The drug works by exploiting kidney cyst cells’ vulnerability to oxidative stress — a state of imbalance between damaging free radicals and beneficial antioxidants.
In a study employing two mouse models of the disease, the researchers found that the drug dramatically shrank kidney cysts without harming healthy kidney cells.